432 results on '"Faivre-Finn, C"'
Search Results
2. OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer
3. EP08.01-03 Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy
4. P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel
5. P1.28-08 Definition of Resectable Stage III Non-Small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group
6. P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC
7. Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK
8. Evaluation of Observer Variation as Natural Experiment to Detect Sensitive Heart Subregions
9. PO-1310 Predictors of outcomes in patients with NSCLC treated with chemoradiotherapy & immunotherapy.
10. MO-0467 Impact of the COVID-19 pandemic on patient outcomes after curative-intent radiotherapy in the UK
11. PO-2117 CTV-free lung planning: Can we reduce toxicity whilst maintaining local control?
12. PO-1676 Optimising heart substructure visibility in 4D planning CT by compensating respiratory motion
13. PD-0901 Methodology to monitor changes in ECG in patients with lung cancer after radiotherapy
14. OC-0608 Do patients with lung cancer and a genetic risk for rheumatoid arthritis have increased toxicity?
15. PO-1653 Auto-contouring of cardiac avoidance region for cardiac sparing lung radiotherapy
16. OC-0611 Lungtech EORTC 22113-08113 prospective multicenter trial: SBRT for central lung tumors.
17. MO-0474 Is comorbidity associated with interruption of RT treatment in patients with lung cancer?
18. 174TiP PRIMALung (EORTC-1901): Prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small cell lung cancer patients
19. 28MO Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation immunotherapy in a phase I drug-radiotherapy platform trial
20. Whole Tumor vs. FDG-Directed Dose Escalation in Patients with Locally Advanced NSCLC: Evaluation of Isotoxic Treatment Plans from the Randomized ARTFORCE PET-Boost Trial
21. Final Results of an International Delphi Consensus Study Regarding the Optimal Management of Radiation Pneumonitis
22. Retrospective Fat Suppression for Lung Radiotherapy Planning with CycleGANs
23. Prise en charge des formes oligométastatiques : l’avis de l’oncologue thoracique
24. EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)
25. EP08.03-005 HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours
26. EP05.01-012 Avoiding Cardiac Toxicity in Lung Cancer Radiotherapy (ACcoLade) Trial - Initial Results
27. Can Real-world Data and Rapid Learning Drive Improvements in Lung Cancer Survival? The RAPID-RT Study
28. PO-1273 Identifying the target: An audit of radiology reports for appropriate use of slice reference numbers
29. PD-0671 Impact of FDG PET in small-cell lung cancer patients treated with curative intent chemoradiotherapy
30. MO-0394 Cardiac Exposure in Lung Cancer Radiotherapy: Systematic Review of Heart Doses Published 2013-2020
31. PO-1631 Feasibility of low-dose 4DCBCT for patient setup and motion measurement
32. OC-0437 Impact of introducing IMRT on curative intent radiotherapy and survival for lung cancer
33. SP-0523 Combining radiotherapy and immunotherapy
34. PD-0673 Validation of the interaction between peritumour density and dose for local relapse in lung SABR
35. OC-0441 Risk of cardiac death increases with dose to cardiac sub structure avoidance region in lung cancer
36. SP-0584 TBC
37. MO-0391 Predicting early mortality using muscle characteristics for patients with lung cancer
38. PO-1877 Initial experience delivering stereotactic radiotherapy to a gluteal metastasis on a 1.5T MR Linac
39. OC-0464 A new model of care for rapid lung SABR treatment planning: Evaluation of the advanced RTT role.
40. MO-0389 Relationship between 4D CT quality and survival after lung cancer radiotherapy
41. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
42. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
43. Initial Clinical Experience of Routine Electronic Patient-Reported Outcome Measures at the Christie NHS Foundation Trust
44. 108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
45. Evaluation of Prognostic and Predictive Models in the Oncology Clinic
46. A novel use for routine CBCT imaging during radiotherapy to detect COVID-19
47. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
48. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study
49. Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK
50. The Routine Clinical Implementation of Electronic Patient-reported Outcome Measures (ePROMs) at The Christie NHS Foundation Trust
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.